Caris & Co Downgrades Response Genetics (RGDX) to Above Average
More News related to RGDX
- Wall Street Media Presents Exclusive Videos from the Collins Stewart Conference and the T. Boone Pickens Press Conference
- Response Genetics, Inc. to Present at the Collins Stewart Fourth Annual Growth Conference
- Response Genetics, Inc. to Hold Annual Meeting of Shareholders Tuesday, June 17, 2008 at 1:00 pm EDT
- David M. Jackson, Ph.D. Joins Response Genetics, Inc. as Executive Vice President
- Caris & Co Downgrades Response Genetics (RGDX) to Above Average
More News related to Downgrades
- Buckingham Research Reinstates Coverage on Family Dollar (FDO) with an Underperform
- Sidoti Downgrades First Place Financial (FPFC) to Neutral
- ARGUS Downgrades Foundry Networks (FDRY) to Sell
- ARGUS Downgrades Lexmark International (LXK) to Hold
- Jefferies Downgrades BJ's Wholesale (BJ) to Hold
Caris & Co downgrades Response Genetics (Nasdaq: RGDX) from Buy to Above Average. Price target dropped to $5.
Response Genetics, Inc. is engaged in the research and development of its clinical diagnostic tests for cancer based on its technologies.
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
